Inmed Pharmaceuticals - Common Shares (INM) closed at $1.44 on October 23, 2026, up 8.3% from the previous close, on volume of 125,640 shares (30-day average 50,186).
Data as of October 23, 2026.
No press releases found.
Mentari’s $200 Million Private Placement and Merger with InMed Signal Ambitious Clinical Push
Market Chameleon (Wed, 22-Jul 5:53 AM ET)
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Inmed Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol INM.
As of October 23, 2026, INM stock price climbed to $1.44 with 125,640 million shares trading.
INM has a beta of 1.97, meaning it tends to be more sensitive to market movements. INM has a correlation of 0.04 to the broad based SPY ETF.
INM has a market cap of $7.91 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INM traded as high as $41.60 and as low as $.58.
INM has underperformed the market in the last year with a return of -29.1%, while the SPY ETF gained +14.3%. In the last 3 month period, INM fell short of the market, returning -22.2%, while SPY returned +3.2%. However, in the most recent 2 weeks INM has outperformed the stock market by returning +5.9%, while SPY returned -2.4%.
INM support price is $1.29 and resistance is $1.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INM shares will trade within this expected range on the day.
